Lipid-Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Components

被引：112

作者：

Kazemian, Pardis ^{[1
,2
]}

Yu, Si-Yue ^{[3
]}

Thomson, Sarah B. ^{[1
,2
]}

Birkenshaw, Alexandra ^{[3
]}

Leavitt, Blair R. ^{[1
,2
]}

Ross, Colin J. D. ^{[3
]}

机构：

[1] Univ British Columbia, Fac Med, Dept Med Genet, Vancouver, BC V6T 1Z3, Canada

[2] BC Childrens Hosp Res Inst, Ctr Mol Med & Therapeut, Vancouver, BC V5Z 4H4, Canada

[3] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC V6T 1Z3, Canada

来源：

MOLECULAR PHARMACEUTICS | 2022年 / 19卷 / 06期

基金：

加拿大健康研究院;

关键词：

lipid nanoparticles; CRISPR; Cas9; genome editing; nanomedicine; gene therapy; IN-VIVO DELIVERY; MESSENGER-RNA; INTRACELLULAR DELIVERY; SYSTEMIC DELIVERY; CATIONIC LIPIDS; BLOOD PROTEINS; HOMING PEPTIDE; GENE-THERAPY; LIPOSOMES; EFFICIENT;

D O I：

10.1021/acs.molpharmaceut.1c00916

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Gene editing mediated by CRISPR/Cas9 systems is due to become a beneficial therapeutic option for treating genetic diseases and some cancers. However, there are challenges in delivering CRISPR components which necessitate sophisticated delivery systems for safe and effective genome editing. Lipid nanoparticles (LNPs) have become an attractive nonviral delivery platform for CRISPR-mediated genome editing due to their low immunogenicity and application flexibility. In this review, we provide a background of CRISPR-mediated gene therapy, as well as LNPs and their applicable characteristics for delivering CRISPR components. We then highlight the challenges of CRISPR delivery, which have driven the significant development of new, safe, and optimized LNP formulations in the past decade. Finally, we discuss considerations for using LNPs to deliver CRISPR and future perspectives on clinical translation of LNP-CRISPR gene editing

引用

页码：1669 / 1686

页数：18

共 50 条

[41] CRISPR/Cas9 and other techniques for genome editing
Hartung, Frank
Schiemann, Jochen
Sprink, Thorben
ZWEITES SYMPOSIUM ZIERPFLANZENZUCHTUNG, 2017, 2017, 457 : 36 - 39
[42] Genome Editing in Cotton with the CRISPR/Cas9 System
Gao, Wei
Long, Lu
Tian, Xinquan
Xu, Fuchun
Liu, Ji
Singh, Prashant K.
Botella, Jose R.
Song, Chunpeng
FRONTIERS IN PLANT SCIENCE, 2017, 8
[43] Advances in therapeutic CRISPR/Cas9 genome editing
Savic, Natasa
Schwank, Gerald
TRANSLATIONAL RESEARCH, 2016, 168 : 15 - 21
[44] A glance at genome editing with CRISPR–Cas9 technology
Antara Barman
Bornali Deb
Supriyo Chakraborty
Current Genetics, 2020, 66 : 447 - 462
[45] Translating CRISPR/Cas9 genome editing into therapeutics
Barnes, T. M.
HUMAN GENE THERAPY, 2016, 27 (11) : A140 - A141
[46] Efficient Mitochondrial Genome Editing by CRISPR/Cas9
Jo, Areum
Ham, Sangwoo
Lee, Gum Hwa
Lee, Yun-Il
Kim, SangSeong
Lee, Yun-Song
Shin, Joo-Ho
Lee, Yunjong
BIOMED RESEARCH INTERNATIONAL, 2015, 2015
[47] CRISPR/Cas9: Transcending the Reality of Genome Editing
Chira, Sergiu
Gulei, Diana
Hajitou, Amin
Zimta, Alina-Andreea
Cordelier, Pierre
Berindan-Neagoe, Ioana
MOLECULAR THERAPY-NUCLEIC ACIDS, 2017, 7 : 211 - 222
[48] Genome editing with AAV using CRISPR/Cas9
Wilson, J. M.
HUMAN GENE THERAPY, 2016, 27 (11) : A18 - A18
[49] CRISPR/Cas9 editing of the genome for cancer modeling
Guernet, Alexis
Grumolato, Luca
METHODS, 2017, 121 : 130 - 137
[50] Expanding the genome-editing range of CRISPR-Cas9 in rice
Xu, Xiuling
NATIONAL SCIENCE REVIEW, 2018, 5 (01) : 6 - 6

← 1 2 3 4 5 →